BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
9.12.2024 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Xypex 2025 International Best Project Awards - Winners Announced19.3.2026 21:00:00 CET | Press release
Xypex announces 2025 award winners recognizing excellence in concrete durability, engineering performance, and crystalline waterproofing technology. VANCOUVER, BC / ACCESS Newswire / March 19, 2026 / Xypex announces the winners of the 2025 International Best Project Awards, recognizing construction projects that demonstrate excellence in concrete durability, engineering performance, and the use of crystalline waterproofing technology. This year's program received more than 80 project submissions from over 20 countries across five continents, reflecting the global reach of Xypex technology and the strength of its international network of distributors, engineers, contractors, and partners. The submissions represented a broad range of projects across infrastructure, general construction, water and wastewater facilities, industrial structures, and small-scale applications. Projects were evaluated based on engineering complexity, construction challenges, durability requirements, and the int
Brookville DMAX Expansion Highlights the Project Work Behind a Major Ohio Manufacturing Investment19.3.2026 16:00:00 CET | Press release
BROOKVILLE, OH / ACCESS Newswire / March 19, 2026 / General Motors' Duramax Engine Plant (DMAX) expansion in Brookville has become one of the region's most significant industrial projects, tied to a $920 million investment supporting Duramax diesel engine production for GM heavy-duty truck programs, including Chevrolet Silverado HD and GMC Sierra HD models. Public reporting has described the Brookville work as adding about 1.1 million square feet to the existing facility which was previously approximately 250,000 square feet. Notably, the project has created and supported hundreds of local jobs as the site expands its manufacturing footprint in southwest Ohio. This expansion quadruples the current facility size and is designed to create over 800 jobs, supporting high demand for diesel trucks. Among the professionals helping carry that work forward is Sabra Sadeghi, a project architect and engineer who served on the Brookville expansion in an on-site role. The project has been praised f
U.S. Polo Assn. Unveils 2026 Spring-Summer Global Collection, Inspired by Coastal Charleston, South Carolina19.3.2026 12:00:00 CET | Press release
Seasonal and Seaside Styles Debut Alongside U.S. Open Polo Championship Capsule WEST PALM BEACH, FL / ACCESS Newswire / March 19, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has launched its sport-inspired Spring-Summer 2026 Global Collection, a vibrant seasonal lineup inspired by coastal Americana and the relaxed spirit of seaside living. The campaign was photographed in historic Charleston, South Carolina, where Rainbow Row's pastel architecture, coastal landscapes, and the heritage of the Hyde Park Polo Club field create the perfect backdrop for the iconic global brand's latest styles.U.S. Polo Assn. 2026 Spring-Summer Global Collection Photoshoot in Charleston, South Carolina The U.S. Polo Assn. campaign once again highlights the authentic connection between the sport of polo and the globally recognized lifestyle brand inspired by the sport. Apparel and accessories from the Spring-Summer 2026 Global Collection are now available. G
Datavault AI Enters into Definitive Agreement to Acquire NYIAX, Combining AI-Driven Data Monetization with Institutional-Grade Market Infrastructure19.3.2026 11:30:00 CET | Press release
Pending acquisition will integrate NYIAX's blockchain-enabled exchange platform, built on globally recognized financial market technology and jointly owned patents to power next-generation digital marketplaces. PHILADELPHIA, PA / ACCESS Newswire / March 19, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the signing of a Definitive Agreement to acquire NYIAX Inc. ("NYIAX"). The acquisition will bring NYIAX's intellectual property portfolio and blockchain-powered trading platform built on a globally recognized financial market infrastructure platform into Datavault AI's organization. The combined company is expected to make institutional-grade, transparent trading infrastructure available to customers and accelerate the planned commercial launches of specialized exchanges. The transaction builds upon an October 2025 letter of inte
Powerverse and Teltonika Energy Partner to Unlock Intelligent Home Energy & Flexibility19.3.2026 08:00:00 CET | Press release
LONDON, UK / ACCESS Newswire / March 19, 2026 / Powerverse has partnered with Teltonika Energy, part of the Teltonika group, a multinational leader in IoT innovation, to deliver an AI-driven home energy ecosystem that enhances user experience, unlocks flexibility services and drives long-term customer value. Teltonika Energy's hardware is built with reliability, connectivity and performance at its core, and its devices are designed to support the next generation of intelligent home energy systems. "Teltonika Energy is globally recognised for its high-quality, IoT-engineered hardware," said Richard Britton, CEO of Powerverse. "We are thrilled to combine their robust devices with our AI-driven platform to help customers move beyond simple smart control and into active market participation. Together, we are delivering a fully integrated, end-to-end solution that makes it effortless for users to lower costs, reduce their carbon footprint, and unlock the full long-term value of home energy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom